CUE Rises 3.3% After $50.0M Private Placement

Cue Biopharma (Nasdaq: CUE) announced a $50.0 million private placement on Jul 9, 2026, and the stock rose 3.3% the same day.

What Cue Biopharma announced

Cue Biopharma said it entered into a securities purchase agreement with a group of accredited investors for a private placement. The deal includes 1,418,071 shares of common stock priced at $33.21 per share. It also includes, for certain investors in lieu of common shares, pre-funded warrants to purchase up to 87,500 shares at $33.209 per pre-funded warrant. Total gross proceeds were described as approximately $50.0 million.

What it means for Cue Biopharma

In plain English, this is Cue raising money by selling stock (and stock-like warrants) directly to a select group of investors, rather than doing a broad public offering. The pricing details show the company set specific purchase prices for the shares and the pre-funded warrants, which can be used to buy shares later. Bringing in approximately $50.0 million in gross proceeds could give Cue more flexibility to fund its work as a clinical-stage biopharmaceutical company focused on therapies targeting functional cures for immunological disorders. The structure — mixing common stock with pre-funded warrants for some buyers — can broaden participation while still delivering cash proceeds to the company.

How the stock reacted

CUE started with an early dip before finishing higher on the day.

Window	Move
5 min	-3.6%
10 min	-0.4%
30 min	-0.0%
1 hour	+1.2%
end of day	+3.3%

On a market-adjusted basis, CUE’s same-day move was +2.8% versus the SPY.